CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 18 enrolled
Drug / intervention
TA-650drug
Likely dose
TA-650 5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01532570
NCT01532570Phase 3Completed
CompareCT.gov

To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650

Tanabe Pharma Corporation·interventional·Posted Feb 14, 2012·Updated Jan 7, 2026

In Brief

A Phase 3 clinical trial evaluating TA-650 for Behcet's Disease and 2 related conditions. Completed, enrolled 18 participants across 6 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650 in patients with Behcet's disease ( BD ) with special lesions after the administration of TA-650 at a dosage of 5 mg/kg in weeks 0, 2, and 6, then every 8 weeks after week 14 up to week 46.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBehcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 14, 2012
Enrollment StartJan 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.4 years ago

Interventions

TA-650drug

TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.